Symptomtext
inadvertently administered Fluzone Quadrivalent instead of Prevnar with no AE; inadvertently administered Fluzone Quadrivalent High-Dose vaccine and Fluzone Quadrivalent instead on same day with no AE; Initial information regarding this unsolicited valid non-serious case was received from Pharmacist via The Agency (Reference number- 00422121) and transmitted to Sanofi on 08-Jan-2021. This case involves a 65 years old female patient who received a dose of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (prefilled syringe, lot UJ565AB, expiration date 30-Jun-2021) via intramuscular route in the left deltoid and then inadvertently received a 0.5ml dose of INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT] (prefilled syringe, lot UJ442AA, expiration 30 June 2021) via intramuscular route in the right deltoid both for prophylactic vaccination (extra dose administered) instead of PNEUMOCOCCAL VACCINE CONJ 7V (CRM197) [PREVENAR] on 08-Jan-2021 (wrong product administered). The patient's medical history, medical treatments, vaccinations and family history were not provided. Patient received no other concomitant vaccines. It was a actual medication error due to wrong vaccine administered and extra dose administered (latency-same day). At the time of reporting, no adverse event was reported. The reporter stated that she grabbed the Fluzone Quadrivalent prefilled syringe box instead of the Prevnar box because the boxes for the two vaccines look very similar. Prevnar was not administered. Repoert stated that doctor information not available since the vaccines were administered at a retail pharmacy. The reporter had been trying to reach the patient, but not spoken to the patient since the error. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.